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erythematosus associated with docetaxel
chemotherapy: a case report
Noelle Y Wong1, Laurie M Parsons2, Martin J Trotter3 and Roger Y Tsang4*Abstract
Background: Drug-induced subacute cutaneous lupus erythematosus is an uncommon disorder associated with
the use of pharmacological agents including systemic chemotherapy.
Case presentation: We report a case of docetaxel-induced subacute cutaneous lupus erythematosus in a 60-year-
old Caucasian female with Sjögren’s syndrome diagnosed 2 months after receiving docetaxel as part of the adjuvant
FEC-D (5-fluorouracil, epirubicin, cyclophosphamide, docetaxel) chemotherapy protocol for early stage breast cancer.
Although the exact mechanisms behind the autoimmune response elicited by docetaxel are unclear, the involvement
of anti-SSA/Ro antibodies has been implicated.
Conclusion: This case highlights the symptom severity and clinical course of docetaxel-induced subacute cutaneous
lupus erythematosus, and highlights the importance of recognizing this uncommon but potentially severe
chemotherapy-associated cutaneous reaction.
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Subacute cutaneous lupus erythematosus (SCLE) is a type
of cutaneous lupus erythematosus, most commonly charac-
terized by photodistributed, non-scarring, papulosquamous
or polycyclic annular plaques. SCLE is often associated with
high titers of anti-SSA/Ro antibodies in the serum, and
roughly 20% of newly diagnosed cases of SCLE are attrib-
uted to a drug or another exacerbating agent [1]. Develop-
ment of drug-induced SCLE has been linked to a number
of pharmacological agents including thiazide diuretics, cal-
cium channel blockers, angiotensin converting enzyme in-
hibitors, and taxanes [2,3]. Taxanes, such as docetaxel and
paclitaxel, belong to the anti-microtubule class of chemo-
therapeutic agents and are commonly used in the systemic
treatment of non-small cell lung cancer, ovarian cancer,
breast cancer, and many other solid tumor malignancies
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unless otherwise stated.induced SCLE in a 60 year old female with Sjögren’s
syndrome diagnosed 2 months after receiving docetaxel
as part of the adjuvant FEC-D (5-fluorouracil, epirubicin,
cyclophosphamide, docetaxel) chemotherapy protocol for
early stage breast cancer, and highlight its severity, clinical
course, and importance in recognizing this uncommon
chemotherapy-associated cutaneous reaction.
Case presentation
A 60-year-old post-menopausal Caucasian woman with
Stage IIB (T2 N1) invasive ductal carcinoma of the left
breast commenced adjuvant chemotherapy with the FEC-
D (5-fluorouracil, epirubicin, cyclophosphamide for 3 -
cycles, followed by docetaxel for 3 cycles) protocol with
G-CSF support (peg-filgrastim) after undergoing breast-
conserving surgery and axillary lymph node dissection.
Her past medical history is significant for chronic benign
neutropenia and Sjögren’s syndrome primarily manifested
by dry eyes, myalgias, and arthralgias, without a pre-
existing history of lupus or other connective tissue dis-
orders. She reports no known drug allergies aside from
a rash from adhesive tapes, and her medication profiletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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days following the administration of the first cycle of FEC
chemotherapy, she developed an exanthema described as a
mild erythematous maculopapular pruritic rash on her ex-
tensor forearms and anterior trunk, which was felt to be
characteristic of a typical chemotherapy-associated rash,
given its near complete resolution prior to her subsequent
chemotherapy cycle. Nonetheless, the rash did recur with
subsequent cycles of FEC chemotherapy, and the switch-
over to docetaxel after 3 cycles of FEC chemotherapy was
delayed by 1 week to allow for its improvement with sup-
portive measures including anti-histamines and a topical
corticosteroid. The decision was then made to begin her
docetaxel treatment with standard dexamethasone pre-
medication. Shortly after the first cycle of docetaxel, how-
ever, she developed a moderately severe, erythematous
desquamating rash initially located on her forearms and an-
terior trunk. The severity and extent of this rash differed
from that seen with FEC. With the second cycle of doce-
taxel, despite the addition of a course of prednisone, the
rash progressed to involve her scalp, cheeks, ears, neck,
back, as well as membranes of the nose and vagina result-
ing in epistaxis and vaginal bleeding (Figure 1). This was
associated with severe burning pains, and facial and peri-
orbital edema. Due to the severity of her presentation, an
urgent dermatology consultation was obtained, with a
working diagnosis of Stevens – Johnson syndrome (Table 1).
A biopsy was performed on her right forearm, and demon-
strated an interface dermatitis with dermal mucin depos-
ition (Figure 2). This pathology was consistent with aFigure 1 Severe erythematous desquamating rash. The rash involved t
membranes of the nose and vagina resulting in epistaxis and vaginal bleeddiagnosis of subacute cutaneous lupus erythematosus,
which was felt to be most likely precipitated by the doce-
taxel exposure. Laboratory and serologic data revealed an
ANA speckled pattern with a titre of 1/2560, high positive
levels of anti-SSA/Ro 60 antigen at a value of 88 AU/mL
(>81 AU/mL is high positive), moderately positive levels of
anti-SSB/La at a value of 66 AU/mL (moderate range is 51-
80 AU/mL), and elevated rheumatoid factor at 113 kU/L. A
decision was made to discontinue chemotherapy after the
second cycle of docetaxel, and following its discontinuation,
the rash fully resolved after two months, with supportive
measures including topical betamethasone cream. During
her treatment course, no discernible worsening of her
Sjögren’s syndrome was reported, which may have been
underreported due to concurrent chemotherapy-related
toxicities.
Conclusions
Drug-induced SCLE is an uncommon cutaneous reaction
associated with chemotherapy use. In the case presented,
given the temporal relationship of the patient’s dermato-
logical toxicities to her chemotherapy treatment, we pos-
tulate that the taxane docetaxel is the most likely culprit.
In the current literature, there have been eight reported
cases of SCLE associated with docetaxel, and five reported
cases of SCLE associated with paclitaxel chemotherapy
[1-13]. Many of the patients in these cases had a back-
ground of preceding autoimmune disease with positive
anti-SSA/Ro antibodies [1-5,8,10,11]. It has been sug-
gested that the presence of serum anti-SSA/Ro antibodieshe forearms, anterior trunk, scalp, cheeks, ears, neck, back, as well as
ing.
Table 1 Clinical and Histological features of Stevens-Johnson syndrome (SJS) and subacute cutaneous lupus erythematosus
(SCLE)





• Mostly drug-related • May be idiopathic or drug-induced Although the rapidity and severity of
symptom progression favored a working
diagnosis of SJS, on clinical grounds it was
not possible to distinguish between SJS
and SCLE in the case presented
• Characterized as dusky erythematous
lesions; lesions tend to be isolated but
can have confluence on the face and
trunk
• Characterized as erythematous,
papulosquamous or polycyclic annular
plaques, typically non-scarring
• Typically involves the trunk, back, and
extremities including palms and soles,
neck, and face; often associated with
painful mucosal surfaces
• Typically consists of photosensitive regions
with lesions confined to sun-exposed skin
(upper trunk/back, shoulders, extensor
arms, neck, lateral aspects of face) with
mid-facial sparing
• Usually occurs within 7 to 21 days after
initiation of the causative drug
• Latent period between drug
administration and the appearance of
symptoms can range from several weeks
to several years (in drug-induced SCLE)
Histological
features
• In early lesions, apoptotic keratinocytes
are observed scattered in the supra-basal
layers of the epidermis
• Epidermal changes and a superficial
lymphocytic infiltrate in the upper dermis
with apoptotic keratinocytes
Histological findings of an interface
dermatitis with dermal mucin deposition is
most consistent with a diagnosis of SCLE
• In late stages, a sub-epidermal blister with
overlying confluent necrosis of the entire
epidermis and spare peri-vascular infiltrate
composed primarily of lymphocytes is seen
• Dermal mucin deposits are commonly
identified
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to a higher risk of developing drug-induced SCLE [4,14].
As taxanes are hypothesized to lead to the appearance or
increase in serum anti-SSA/Ro antibodies [10], the risk of
drug-induced SCLE would be further heightened given a
patient with pre-existing positive titres due to an auto-
immune disorder. Docetaxel targets dividing cells and acts
to stabilize microtubule assembly, which leads to G2/M
phase cell cycle arrest followed by apoptosis [15]. Apop-
totic products can then in turn incite an immunogenic re-
sponse against DNA-histone and RNA-protein complexes
[16]. Therefore, in an individual with a pre-existing auto-
immune disorder in which antibodies against nucleopro-
teins already exist (such as anti-SSA/Ro), increased levels
of apoptotic products from chemotherapy could stimulate
an exacerbated immune response, and manifest as severe
cutaneous lesions [17].
Drug-induced SCLE does not differ from idiopathic
SCLE in its clinical, immunological, and histopathological
characteristics [15]. Therefore, the diagnosis of drug-
induced SCLE is characterized by the development of dif-
fuse cutaneous lesions following administration of an
offending agent, and its resolution upon discontinuation
of the drug. In the present case, the clinical and patho-
logical features are compatible with drug-induced SCLE,
most likely secondary to docetaxel. The use of dexametha-
sone likely masked the true severity of the rash. Despite
the addition of a course of systemic corticosteroids withprednisone with her second cycle of docetaxel, the rash
rapidly progressed. The patient’s history of Sjögren’s syn-
drome with high levels of serum anti-SSA/Ro antibodies
likely predisposed her to the development of the extensive
and severe cutaneous lesions. Anti-SSA/Ro antigens have
been seen to preferentially relocate to the surface of cul-
tured keratinocytes that had been irradiated with ultravio-
let radiation [18]. It should be noted that her skin lesions
were distributed over photo-exposed areas of her body,
suggesting that induction of photosensitivity may have
been a contributing mechanism to the development of her
skin eruptions. Lastly, the patient also had a history of
chronic benign neutropenia, and was given peg-filgrastim
with her chemotherapy cycles to support her white blood
cell and neutrophil counts. The increased number of cir-
culating white blood cells and neutrophils may also have
contributed to a heightened immune response, further ex-
acerbating her cutaneous reaction to the docetaxel.
Although SCLE is classically characterized as either idio-
pathic or drug-induced, there has been sufficient evidence
in the literature to consider certain cases of SCLE to have
a paraneoplastic etiology [19]. There have been multiple
reports of SCLE arising in the setting of internal malig-
nancy including two cases in breast adenocarcinomas [20].
Like other paraneoplastic dermatoses, presentations of
paraneoplastic SCLE follow the criteria in that the cutane-
ous findings appear temporally after development of the
malignancy, and their clinical courses typically run parallel
Figure 2 Photomicrographs of a skin biopsy. Photomicrographs
show an interface dermatitis with associated mid-dermal peri-vascular
lymphocytic inflammation (A: hematoxylin and eosin, 100X) and
dermal mucin deposition (B: Hale’s colloidal iron, 100X).
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successful treatment of the malignancy. However, because
of the role of chemotherapy treatments in causing tumor
regression and the timing of its administration, it may
sometimes be difficult to differentiate drug-induced SCLE
from paraneoplastic SCLE. This is especially true if the ap-
pearance of skin eruptions occurs shortly after beginning
systemic chemotherapy. However, if the lesions regress
quickly after discontinuing chemotherapy, as was observed
in this case, then the etiology would be most compatible
with drug-induced SCLE. Regardless, it is important to also
consider paraneoplastic SCLE in the differential diagnosis.
Drug-induced subacute cutaneous lupus erythematosus
(SCLE) is an uncommon but potentially severe disease
state associated with docetaxel chemotherapy. The clin-
ician needs to recognize and consider this entity in the dif-
ferential diagnosis of chemotherapy-associated cutaneous
reactions, given its severity, and the importance of discon-
tinuing the offending agent as primary management. Al-
though the exact mechanisms behind drug-induced SCLE
remain unclear, patients with a pre-existing autoimmunedisorder appear to have a higher incidence when exposed
to offending agents including chemotherapy. The identifi-
cation and discontinuation of the offending agent is essen-
tial in the management of drug-induced autoimmune
reactions.
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